Abstract 2135P
Background
G8 and GA assessments to screen for frailty and facilitate appropriate interventions have been recommended by the International Society for Geriatric Oncology in older adults with cancer. The main objective of this study is to evaluate the impact of G8 and GA-based interventions on the QoL of older Asian adults with cancer.
Methods
This is a prospective study of cancer patients aged ≥70 treated at the National University Cancer Institute, Singapore. The G8, CGA, and EORTC QLQ 30 questionnaires were administered at study entry. Targeted interventions were offered by the multi-disciplinary geriatric oncology (GO) service. After three months, a follow-up EORTC QLQ 30 was repeated for those who required geriatric interventions. Primary outcome measure was comparison of pre/post- EORTC QLQ 30 scores.
Results
N=230 patients were accrued. Median age was 74 (range:70-90). Majority were male (56%), diagnosed with gastrointestinal cancers (35%) and receiving palliative intent treatment (60%). Based on GA, 11% were classified as frail, 58% as pre-frail and 31% as fit. 79% had G8 scores ≤14. Pre-frail, frail and those with G8 ≤14 had lower baseline EORTC QOL function scores and higher EORTC QOL symptom scores (p<0.05). They also had significantly shorter overall survival (OS) compared to fit or with patients G8>14. (HR=2.54 95% CI 1.46-4.43, p=0.001 for frail vs fit patients; HR=1.72 95% CI 1.18-2.53, p=0.005 for pre-frail vs fit patients; HR=1.51 95% CI 1.05-2.18, p=0.027 for G8 ≤14 vs >14). GO interventions were suggested for 144 patients with 104 patients completing a 2nd EORTC QOL questionnaire. These patients reported significant improvements in the EORTC emotional and social functioning domains (mean difference +4.6, p<0.001 and +12.3 p<0.001, respectively), a significant reduction in the EORTC symptom scale of pain, insomnia, constipation, and financial difficulties (mean difference -5.8 p=0.003, -8.3 p<0.001, -9.0 p<0.001, and -6 p=0.01), with no significant deterioration in other QOL domains.
Conclusions
Geriatric assessment-based targeted interventions delivered by a multidisciplinary GO service significantly improved multiple QOL domains in older Asian adults undergoing cancer treatment.
Clinical trial identification
DSRB Study Reference Number: 2017/00214.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Singapore Cancer Society.
Disclosure
C.E. Chee: Financial Interests, Institutional, Advisory Board: Merck, AstraZeneca, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07